UK Innovation & Science Seed Fund (UKI2S) invests in early-stage businesses and spinouts emerging from the United Kingdom’s science and knowledge base. Its stated focus spans defence and security, engineering biology, fusion, knowledge assets, partner innovation, and space, with investment activity concentrated at pre-seed and seed stages.
ukinnovationscienceseedfund.co.ukCrawled Oct 16, 2026
FPC reflects on developments in 2024, particularly at its early-stage innovation-focused fund, UK Innovation & Science Seed Fund (UKI2S).
Early stage investments into the UK’s brightest tech startups are dwindling year on year, according to Dealroom which revealed the lowest deal count since 2016.
Productive Machines is on a mission to revolutionise the productivity of machine tools. It uses digital twin technology to simulate millions of different machine settings in order to find the most optimal combinations that minimise waste and energy consumption.
Building sustainability with engineering biology and AI. NetZero by 2030. Responsible investment. Environmental action. Social inclusion. Impact-first – that's the mission. The driving force behind UKI2S.
Aquark raised a seed round from NATO Innovation Fund, EIFO, UKI2S (managed by Future Planet Capital), and MBDA to scale and increase the availability of its quantum sensing technology.
Proprietary Fermentation Process Mimics the Muscle Structure of Whole-Cut Meat, Promoting Health with Zero Cholesterol and Reducing Emissions by 93%.
A Scottish underwater robotics firm has received a seven-figure investment into its plans to revolutionise operations in the energy and security sectors.
UKI2S provides insights, interviews, news and resources, including news from UKI2S and its portfolio companies.
UKI2S is a UK pre-seed+ fund with £150 million in assets under management.
Agilent leads a funding round in HALO, while UKI2S and MEIF follow their previous investments.
Aug 2026 · UKI2SNews article
SMG secures £6 million to strengthen UK sovereign semiconductor capability, with backing from UKI2S. The funding is intended to accelerate the advanced manufacturing pioneer’s commercial growth.
Jul 2026 · UKI2SNews article
Revolver Therapeutics secures £572k in further funding led by QantX to inhibit transcription factor drug targets for cancer. UKI2S and the University of Bath also participate with follow-on investment.
Jul 2026 · UKI2SNews article
Optera has raised £3m in a round led by UKI2S to establish and scale its UK headquarters and engineering team. The funding supports a UK hub for space domain awareness.
Jun 2026 · UKI2SNews article